Prediagnosis Insights Into Amyotrophic Lateral Sclerosis: Clinical Symptoms and Medication Use

Area of Science:

• Neurology
• Epidemiology
• Biostatistics

Background:

• Amyotrophic Lateral Sclerosis (ALS) has a long latency period, with preclinical characteristics poorly understood.
• Investigating pre-diagnostic features of ALS is crucial for understanding disease mechanisms.
• This study utilizes UK Biobank data to explore early signs and medication use in ALS patients.

Purpose of the Study:

• To compare pre-diagnostic symptoms and medication use in ALS patients against Alzheimer's Disease (AD) and Parkinson's Disease (PD).
• To identify potential risk factors for ALS development, such as medication use.
• To gain insights into the underlying mechanisms of ALS progression.

Main Methods:

• Utilized UK Biobank data, including self-reports, hospital records, and death registry data.
• Employed propensity score matching to compare ALS cases with matched AD and PD cohorts.
• Applied Cox regression analysis to assess medication use associations with ALS risk and post-diagnosis mortality.

Main Results:

• Observed 753 ALS cases with an incidence rate of 10.58 per 100,000 person-years.
• Pre-diagnostic falls were more frequent in ALS than AD (11.3% vs. 3.2%) but less frequent than PD (10.7% vs. 28.3%).
• ALS patients showed fewer psychiatric and autonomic symptoms compared to PD patients; calcium channel blocker use was linked to increased ALS risk (aHR 1.61).

Conclusions:

• Pre-diagnostic falls are a notable feature differentiating ALS from AD and PD.
• ALS presents with fewer psychiatric and autonomic symptoms compared to PD.
• Calcium channel blocker use may be a potential risk factor for developing ALS.